Advertisement reMYND - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

reMYND

Logo
  • Latest
  • About
  • Products & Services
  • Press Releases
  • Case Studies
  • White Papers
  • Videos
  • Contact
  • Opinion Industry
WHITE PAPERS
PRODUCTS & SERVICES
Alzheimer in vivo CRO
Alzheimer models
View all Products & Services
Quick Contact reMYND
LATEST PRESS RELEASES
March 5, 2013

Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment

reMYND NV announced today that Bernd Bohrmann (Neuroscience, Roche) is presenting preclinical efficacy data at the leading AD/PD conference held...
pharmacuetical business review
January 2, 2013

reMYND’s CRO receives governmental grant for a continued innovation of its offering

On its Board Meeting of April 28th 2011, the governmental Agency for Innovation by Science and Technology (IWT) has approved...
pharmacuetical business review
View all Press Releases


LATEST VIDEOS

reMYND

reMYND's Contract Research Organization (CRO) is a trusted research partner specialized in the pre-clinical in-vivo testing of all experimental Alzheimer treatments. By contributing our extensive expertise and experience we are helping our clients in understanding as fast as possible the therapeutic in-vivo effects of their lead preclinical Alzheimer therapies.

Research partner in the preclinical in-vivo testing of all types of Alzheimer treatments

  • World-class CRO with clients in US, Europe and Japan, including the leading biotechs and 6 of the top 10 pharmaco’s
  • Research partner in the preclinical in-vivo testing of all types of Alzheimer treatments
    • small molecule and immunization strategies
    • prophylactic and curative treatments
    • pharmaceuticals and nutraceuticals
  • Mastering all routes of administration (e.g., gavage, stereotactic injection in brain, ip, sc, iv)
  • Offering a set of unique and validated animal models (based on a set of human clinical mutations)
  • With a broad testing window for a whole portfolio of behavioral, immunohistochemical and biochemical read-outs, both in brain and csf
  • Committed to a short response time allowing rapid study start also with aged mice

 

reMYNDreMYND’s proprietary Alzheimer mouse models are based on the human clinical APP-London allele APP[V717I]– a preferred model for anti-BACE1 approaches – either alone or in combination with the human clinical PS1[A246E] allele, now extended to a TAU[P301L] and APPxTAU model, the latter combining both amyloid plaque and tau tangle pathology.

High client satisfaction is our key driver, committing us to excel in communication, dedication and flexibility

A concise overview presentation of reMYND’s Contract Research Offering can be downloaded here. For more information and all inquiries, please contact Dr. An Tanghe, CRO Manager.

Contact

An Tanghe, PhD
Manager Contract Research
Bio-Incubator (Wetenschapspark)
Gaston Geenslaan 1
3001 Leuven-Heverlee
Belgium
Tel: +32 16 75 14 22
Fax: +32 16 75 14 21
Email: An.Tanghe@remynd.com
URL: www.remynd.com/contract_research

Quick Contact reMYND


Top Products from reMYND


Alzheimer in vivo CRO

Alzheimer models
View all Products & Services

Alzheimer in vivo CRO

reMYND's CRO is a trusted research partner in the preclinical in-vivo testing of all types of experimental Alzheimer treatments:

small molecule and immunization strategies;prophylactic and curative treatments;pharmaceuticals and nutraceuticals;testing of tau and Abeta directed approaches, as well as other hypothesesWe take care of the whole study trajectory, ranging from the breeding and aging of the mouse, over the treatment of the mice with the experimental therapy, and a detailed pharmacology assessment via behavior testing…
MORE ABOUT THIS PRODUCT
BROCHURE AVAILABLE

Alzheimer models

reMYND's proprietary Alzheimer mouse models are based on the human clinical APP-London allele APP[V717I]- a preferred model for anti-BACE1 approaches - either alone or in combination with the human clinical PS1[A246E] allele, now extended to a TAU[P301L] and APPxTAU model, the latter combining both amyloid plaque and tau tangle pathology.

reMYND's proprietary APP[V717I] mice, modeling a progressive amyloid-o-pathy and therefore serving as an excellent model for Alzheimer's disease, is also available in combination with PS1[A246E]; the bigenic APPxPS1 model showing the same pathological hallmarks but with a different timing of onset and severity.See below for a glance at the difference in pathology progression between both…
MORE ABOUT THIS PRODUCT
BROCHURE AVAILABLE
Quick Contact reMYND
Quick Contact reMYND
Quick Contact reMYND


Quick Contact reMYND
Quick Contact reMYND
Quick Contact reMYND


Contact reMYND

Optional Data

Almost there, complete this form and hit the submit button to complete your registration.

Confirmation

Finally, complete a quick security check and confirm terms and conditions:

Quick Contact reMYND